FDA classifies nerve stimulator for fibromyalgia as class II device

The Food and Drug Administration has officially classified a specific type of transcutaneous electrical nerve stimulator, or TENS unit, intended to treat fibromyalgia symptoms. The agency placed the device into Class II, which means it requires special controls to ensure safety and effectiveness but does not need the rigorous premarket approval process reserved for higher-risk devices.

Why it matters: This action reduces regulatory hurdles for companies making nerve stimulators for fibromyalgia. It allows these specific devices to reach patients faster by streamlining the path to market while maintaining safety standards through special controls like labeling and performance testing. The change is primarily administrative but has practical implications for device manufacturers and potentially for patient access to treatment options.

Who it affects

• Medical device manufacturers, specifically those producing transcutaneous electrical nerve stimulators for fibromyalgia

---

This final order was issued by the Food and Drug Administration within the Department of Health and Human Services; readers should consult the original Federal Register document for full regulatory text and compliance requirements.

Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document